Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation

Yoshihiro Inamoto; Igor Petriček; Linda Burns; Saurabh Chhabra; Zachariah DeFilipp; Peiman Hematti; Alicia Rovó; Raquel Schears; Ami Shah; Vaibhav Agrawal; Aisha Ahmed; Ibrahim Ahmed; Asim Ali; Mahmoud Aljurf; Hassan Alkhateeb; Amer Beitinjaneh; Neel Bhatt; Dave Buchbinder; Michael Byrne; Natalie Callander; Kristina Fahnehjelm; Nosha Farhadfar; Robert Peter Gale; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C. Hildebrandt; Erich Horn; Ann Jakubowski; Rammurti T. Kamble; Jason Law; Catherine Lee; Sunita Nathan; Olaf Penack; Ravi Pingali; Pinki Prasad; Drazen Pulanic; Seth Rotz; Aditya Shreenivas; Amir Steinberg; Khalid Tabbara; André Tichelli; Baldeep Wirk; Jean Yared; Grzegorz W. Basak; Minoo Battiwalla; Rafael Duarte; Bipin N. Savani; Mary E.D. Flowers; Bronwen E. Shaw; Nuria Valdés-Sanz

doi:10.1016/j.bbmt.2018.11.033

Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation

Yoshihiro Inamoto
, Igor Petriček
, Linda Burns
, Saurabh Chhabra
, Zachariah DeFilipp
, Peiman Hematti
, Alicia Rovó
, Raquel Schears
, Ami Shah
, Vaibhav Agrawal
, Aisha Ahmed
, Ibrahim Ahmed
, Asim Ali
, Mahmoud Aljurf
, Hassan Alkhateeb
, Amer Beitinjaneh
, Neel Bhatt
, Dave Buchbinder
, Michael Byrne
, Natalie Callander

Kristina Fahnehjelm, Nosha Farhadfar, Robert Peter Gale, Siddhartha Ganguly, Shahrukh Hashmi, Gerhard C. Hildebrandt, Erich Horn, Ann Jakubowski, Rammurti T. Kamble, Jason Law, Catherine Lee, Sunita Nathan, Olaf Penack, Ravi Pingali, Pinki Prasad, Drazen Pulanic, Seth Rotz, Aditya Shreenivas, Amir Steinberg, Khalid Tabbara, André Tichelli, Baldeep Wirk, Jean Yared, Grzegorz W. Basak, Minoo Battiwalla, Rafael Duarte, Bipin N. Savani, Mary E.D. Flowers, Bronwen E. Shaw, Nuria Valdés-Sanz

Internal Medicine

Producción científica: Review article › revisión exhaustiva

20 Citas (Scopus)

Resumen

Non-graft-versus-host disease (GVHD)ocular complications are generally uncommon after hematopoietic cell transplantation (HCT)but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.

Idioma original	English
Páginas (desde-hasta)	e145-e154
Publicación	Biology of Blood and Marrow Transplantation
Volumen	25
N.º	5
DOI	https://doi.org/10.1016/j.bbmt.2018.11.033
Estado	Published - may 2019

Nota bibliográfica

Publisher Copyright:
© 2018 American Society for Blood and Marrow Transplantation

Financiación

Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Institute of Allergy and Infectious Diseases, National Cancer Institute (NCI), and National Heart, Lung, and Blood Institute (NHLBI); Grant/Cooperative Agreement 4U10HL069294 from the NHLBI and NCI; Contract HHSH250201200016C with the Health Resources and Services Administration; Grants N00014-17-1-2388 and N0014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, *Amgen, *Amneal Biosciences, *Angiocrine Bioscience, Anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara Biotherapeutics, Be the Match Foundation, *bluebird bio, *Bristol Myers Squibb Oncology; *Celgene, Cerus, *Chimerix, Fred Hutchinson Cancer Research Center, Gamida Cell, Gilead Sciences, HistoGenetics, Immucor, *Incyte, Janssen Scientific Affairs, *Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Medac, MedImmune, Medical College of Wisconsin, *Mediware, *Merck & Co, *Mesoblast, MesoScale Diagnostics, Millennium, *Miltenyi Biotec, National Marrow Donor Program, *Neovii Biotech NA, Novartis Pharmaceuticals, Otsuka Pharmaceutical, the Patient-Centered Outcomes Research Institute, *Pfizer, *Pharmacyclics, PIRCHE, *Sanofi Genzyme, *Seattle Genetics, Shire, Spectrum Pharmaceuticals, St. Baldrick's Foundation, *Sunesis Pharmaceuticals, Swedish Orphan Biovitrum, Takeda Oncology, Telomere Diagnostics, and the University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government. Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Institute of Allergy and Infectious Diseases, National Cancer Institute (NCI) , and National Heart, Lung, and Blood Institute (NHLBI) ; Grant/Cooperative Agreement 4U10HL069294 from the NHLBI and NCI ; Contract HHSH250201200016C with the Health Resources and Services Administration ; Grants N00014-17-1-2388 and N0014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, *Amgen, *Amneal Biosciences, *Angiocrine Bioscience, Anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara Biotherapeutics, Be the Match Foundation, *bluebird bio, *Bristol Myers Squibb Oncology; *Celgene, Cerus, *Chimerix, Fred Hutchinson Cancer Research Center, Gamida Cell, Gilead Sciences, HistoGenetics, Immucor, *Incyte, Janssen Scientific Affairs, *Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Medac, MedImmune, Medical College of Wisconsin, *Mediware, *Merck & Co, *Mesoblast, MesoScale Diagnostics, Millennium, *Miltenyi Biotec, National Marrow Donor Program, *Neovii Biotech NA, Novartis Pharmaceuticals, Otsuka Pharmaceutical, the Patient-Centered Outcomes Research Institute, *Pfizer, *Pharmacyclics, PIRCHE, *Sanofi Genzyme, *Seattle Genetics, Shire, Spectrum Pharmaceuticals, St. Baldrick's Foundation, *Sunesis Pharmaceuticals, Swedish Orphan Biovitrum, Takeda Oncology, Telomere Diagnostics, and the University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government. Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Institute of Allergy and Infectious Diseases, National Cancer Institute (NCI), and National Heart, Lung, and Blood Institute (NHLBI); Grant/Cooperative Agreement 4U10HL069294 from the NHLBI and NCI; Contract HHSH250201200016C with the Health Resources and Services Administration; Grants N00014-17-1-2388 and N0014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, *Amgen, *Amneal Biosciences, *Angiocrine Bioscience, Anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara Biotherapeutics, Be the Match Foundation, *bluebird bio, *Bristol Myers Squibb Oncology; *Celgene, Cerus, *Chimerix, Fred Hutchinson Cancer Research Center, Gamida Cell, Gilead Sciences, HistoGenetics, Immucor, *Incyte, Janssen Scientific Affairs, *Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Medac, MedImmune, Medical College of Wisconsin, *Mediware, *Merck & Co, *Mesoblast, MesoScale Diagnostics, Millennium, *Miltenyi Biotec, National Marrow Donor Program, *Neovii Biotech NA, Novartis Pharmaceuticals, Otsuka Pharmaceutical, the Patient-Centered Outcomes Research Institute, *Pfizer, *Pharmacyclics, PIRCHE, *Sanofi Genzyme, *Seattle Genetics, Shire, Spectrum Pharmaceuticals, St. Baldrick's Foundation, *Sunesis Pharmaceuticals, Swedish Orphan Biovitrum, Takeda Oncology, Telomere Diagnostics, and the University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government. *Corporate members. Conflict of interest statement: There are no conflicts of interest to disclose. Authorship statement: Y.I. I.P. and N.S. contributed equally to this work.

Financiadores	Número del financiador
Amneal Biosciences, *Angiocrine Bioscience
National Institutes of Health (NIH)
U.S. Department of Defense
Office of Naval Research Naval Academy
National Heart, Lung, and Blood Institute (NHLBI)	HHSH250201200016C, N00014-17-1-2388, N0014-17-1-2850, U10HL069294
National Childhood Cancer Registry – National Cancer Institute
National Institute of Allergy and Infectious F32-AI286447 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI168214 Jason W. Rosch Diseases National Institute of Allergy and Infectious P30 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R00-AI166116 Christopher D. Radka Diseases National Institute of Allergy and Infectious T32-AI106700 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI192221 Jason W. Rosch Diseases National Inst...
Health Resources and Services Administration
Pfizer
Patient-Centered Outcomes Research Institute
Minnesota State University-Mankato
Novartis Pharmaceuticals Corporation
U.S. Navy Air Systems Command
Actinium Pharmaceuticals Incorporated
National Computational Infrastructure
Government of South Australia
Otsuka Pharmaceutical Co Ltd.

ASJC Scopus subject areas

Hematology
Transplantation

Acceder al documento

10.1016/j.bbmt.2018.11.033

Otros archivos y enlaces

Huella

Profundice en los temas de investigación de 'Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation'. En conjunto forman una huella única.

Citar esto

Inamoto, Y., Petriček, I., Burns, L., Chhabra, S., DeFilipp, Z., Hematti, P., Rovó, A., Schears, R., Shah, A., Agrawal, V., Ahmed, A., Ahmed, I., Ali, A., Aljurf, M., Alkhateeb, H., Beitinjaneh, A., Bhatt, N., Buchbinder, D., Byrne, M., ... Valdés-Sanz, N. (2019). Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 25(5), e145-e154. https://doi.org/10.1016/j.bbmt.2018.11.033

Inamoto, Yoshihiro ; Petriček, Igor ; Burns, Linda et al. / Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation : Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. En: Biology of Blood and Marrow Transplantation. 2019 ; Vol. 25, N.º 5. pp. e145-e154.

@article{bd7c83960ce04b2b8e6cf16ddd9b3d1b,

title = "Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation",

abstract = "Non-graft-versus-host disease (GVHD)ocular complications are generally uncommon after hematopoietic cell transplantation (HCT)but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.",

keywords = "Complication, Eye, Hematopoietic cell transplantation, Prevention, Review, Treatment",

author = "Yoshihiro Inamoto and Igor Petri{\v c}ek and Linda Burns and Saurabh Chhabra and Zachariah DeFilipp and Peiman Hematti and Alicia Rov{\'o} and Raquel Schears and Ami Shah and Vaibhav Agrawal and Aisha Ahmed and Ibrahim Ahmed and Asim Ali and Mahmoud Aljurf and Hassan Alkhateeb and Amer Beitinjaneh and Neel Bhatt and Dave Buchbinder and Michael Byrne and Natalie Callander and Kristina Fahnehjelm and Nosha Farhadfar and Gale, \{Robert Peter\} and Siddhartha Ganguly and Shahrukh Hashmi and Hildebrandt, \{Gerhard C.\} and Erich Horn and Ann Jakubowski and Kamble, \{Rammurti T.\} and Jason Law and Catherine Lee and Sunita Nathan and Olaf Penack and Ravi Pingali and Pinki Prasad and Drazen Pulanic and Seth Rotz and Aditya Shreenivas and Amir Steinberg and Khalid Tabbara and Andr{\'e} Tichelli and Baldeep Wirk and Jean Yared and Basak, \{Grzegorz W.\} and Minoo Battiwalla and Rafael Duarte and Savani, \{Bipin N.\} and Flowers, \{Mary E.D.\} and Shaw, \{Bronwen E.\} and Nuria Vald{\'e}s-Sanz",

note = "Publisher Copyright: {\textcopyright} 2018 American Society for Blood and Marrow Transplantation",

year = "2019",

month = may,

doi = "10.1016/j.bbmt.2018.11.033",

language = "English",

volume = "25",

pages = "e145--e154",

number = "5",

}

Inamoto, Y, Petriček, I, Burns, L, Chhabra, S, DeFilipp, Z, Hematti, P, Rovó, A, Schears, R, Shah, A, Agrawal, V, Ahmed, A, Ahmed, I, Ali, A, Aljurf, M, Alkhateeb, H, Beitinjaneh, A, Bhatt, N, Buchbinder, D, Byrne, M, Callander, N, Fahnehjelm, K, Farhadfar, N, Gale, RP, Ganguly, S, Hashmi, S, Hildebrandt, GC, Horn, E, Jakubowski, A, Kamble, RT, Law, J, Lee, C, Nathan, S, Penack, O, Pingali, R, Prasad, P, Pulanic, D, Rotz, S, Shreenivas, A, Steinberg, A, Tabbara, K, Tichelli, A, Wirk, B, Yared, J, Basak, GW, Battiwalla, M, Duarte, R, Savani, BN, Flowers, MED, Shaw, BE & Valdés-Sanz, N 2019, 'Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation', Biology of Blood and Marrow Transplantation, vol. 25, n.º 5, pp. e145-e154. https://doi.org/10.1016/j.bbmt.2018.11.033

Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. / Inamoto, Yoshihiro; Petriček, Igor; Burns, Linda et al.
En: Biology of Blood and Marrow Transplantation, Vol. 25, N.º 5, 05.2019, p. e145-e154.

Producción científica: Review article › revisión exhaustiva

TY - JOUR

T1 - Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation

T2 - Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation

AU - Inamoto, Yoshihiro

AU - Petriček, Igor

AU - Burns, Linda

AU - Chhabra, Saurabh

AU - DeFilipp, Zachariah

AU - Hematti, Peiman

AU - Rovó, Alicia

AU - Schears, Raquel

AU - Shah, Ami

AU - Agrawal, Vaibhav

AU - Ahmed, Aisha

AU - Ahmed, Ibrahim

AU - Ali, Asim

AU - Aljurf, Mahmoud

AU - Alkhateeb, Hassan

AU - Beitinjaneh, Amer

AU - Bhatt, Neel

AU - Buchbinder, Dave

AU - Byrne, Michael

AU - Callander, Natalie

AU - Fahnehjelm, Kristina

AU - Farhadfar, Nosha

AU - Gale, Robert Peter

AU - Ganguly, Siddhartha

AU - Hashmi, Shahrukh

AU - Hildebrandt, Gerhard C.

AU - Horn, Erich

AU - Jakubowski, Ann

AU - Kamble, Rammurti T.

AU - Law, Jason

AU - Lee, Catherine

AU - Nathan, Sunita

AU - Penack, Olaf

AU - Pingali, Ravi

AU - Prasad, Pinki

AU - Pulanic, Drazen

AU - Rotz, Seth

AU - Shreenivas, Aditya

AU - Steinberg, Amir

AU - Tabbara, Khalid

AU - Tichelli, André

AU - Wirk, Baldeep

AU - Yared, Jean

AU - Basak, Grzegorz W.

AU - Battiwalla, Minoo

AU - Duarte, Rafael

AU - Savani, Bipin N.

AU - Flowers, Mary E.D.

AU - Shaw, Bronwen E.

AU - Valdés-Sanz, Nuria

PY - 2019/5

Y1 - 2019/5

N2 - Non-graft-versus-host disease (GVHD)ocular complications are generally uncommon after hematopoietic cell transplantation (HCT)but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.

AB - Non-graft-versus-host disease (GVHD)ocular complications are generally uncommon after hematopoietic cell transplantation (HCT)but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.

KW - Complication

KW - Eye

KW - Hematopoietic cell transplantation

KW - Prevention

KW - Review

KW - Treatment

UR - https://www.scopus.com/pages/publications/85059228103

UR - https://www.scopus.com/pages/publications/85059228103#tab=citedBy

U2 - 10.1016/j.bbmt.2018.11.033

DO - 10.1016/j.bbmt.2018.11.033

M3 - Review article

C2 - 30521975

AN - SCOPUS:85059228103

SN - 1083-8791

VL - 25

SP - e145-e154

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 5

ER -

Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P et al. Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation. 2019 may;25(5):e145-e154. doi: 10.1016/j.bbmt.2018.11.033